Florida is currently home to 3758 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of BGB-11417 in Participants With Myeloid Malignancies
Recruiting
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Tampa General Hospital, Tampa, Florida
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
Recruiting
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Palm Beach Heart & Vascular, LLC, Boynton Beach, Florida
Conditions: Peripheral Vascular Diseases
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Recruiting
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Florida Cancer Specialists - Sarasota, Sarasota, Florida
Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Recruiting
The study purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Miami Hospital and Clinics, Miami, Florida
Conditions: Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Recruiting
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida
Conditions: Metastatic Urothelial Cancer
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Recruiting
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Gender:
ALL
Ages:
All
Trial Updated:
04/11/2025
Locations: The Mayo Clinic - Jacksonville, Davis-E, Jacksonville, Florida
Conditions: Neoplasms
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Recruiting
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
Gender:
ALL
Ages:
All
Trial Updated:
04/11/2025
Locations: Miami Cancer Institute of Baptist Health, Inc., Miami, Florida
Conditions: Neoplasms
Hairy Cell Leukemia Patient Data Registry
Recruiting
The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality and improving the quality of life of patients diagnosed or living with hairy cell leukemia. With approximately 1,000 new cases of this rare disease identified in the US each year, HCL represents 2% of all cases of leukemia in adults. Considering the rarity of this chronic leukemia, the Hairy Cell Leukemia Foundation (HCLF), in part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Miami/Soffer Clinical Research Center, Miami, Florida
Conditions: Leukemia, Other
iTBS/fMRI Study of Apex Control
Recruiting
The objective of this study is to examine the effect of transcranial magnetic stimulation (TMS) on the prefrontal cortex and posterior parietal cortex.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/10/2025
Locations: Florida State University Psychology Department Building, Tallahassee, Florida
Conditions: Transcranial Magnetic Stimulation
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Recruiting
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/10/2025
Locations: Investigative Site, DeLand, Florida
Conditions: Viral Hepatitis
Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
Recruiting
Dual antiplatelet therapy (DAPT) with low-dose aspirin and a P2Y12 inhibitor is the current standard of care in patients with coronary artery disease experiencing an acute event or undergoing percutaneous coronary intervention. However, the ischemic benefits are counterbalanced by a significant increase in bleeding events. Over time, different DAPT de-escalation strategies have been developed to reduce the bleeding risk while maintaining the ischemic protection, but there is currently no head-to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: University of Florida, Jacksonville, Florida
Conditions: Coronary Artery Disease
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
Recruiting
The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participants have when taking BGB-B455? The study has two parts: * Phase 1a: dose escalation and safety expansion * Phase 1b: dose expansion
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Adventhealth, Celebration, Florida
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor